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Background: We identified the clinical features of 61 cases of multiple myeloma (MM) patients over 65 years and
analyzed the treatment and prognosis of the era of new drugs in elderly patients.
Methods: We identified 61 newly diagnosed symptomatic multiple myeloma (NDMM) among elderly Chinese patients
more than 65 years old diagnosed from 2006 to 2012.
Results: Of the 205 consecutive MM patients whom we reviewed, 61 (29.76 %) cases were NDMM patients
aged more than 65 years and the others were younger than 65 years old. Among them, 40 (65.6 %) cases
were in end-stage (ISS stage III); meanwhile, 19 (31.2 %) cases of them had MM with extramedullary plasmacytoma
(EMP), observed in 42.1 % patients at diagnosis, and the top three incidence of position were spinal canal, pleural, and
soft tissue. In the whole column, the median follow-up was 38 months and median age was 72.5 years. Patients
received bortezomib- or thalidomide-containing regimens as initial therapy. Comparing the two treatment groups, the
complete remission (CR)/near-complete remission (nCR) rate was significantly higher in the bortezomib-containing
regimens (61.5 vs.18.18 %, P = 0.001), no difference in progression-free survival (PFS) and overall survival (OS). Patients of
age over 75 years had shorter OS than those of age over 65 years (49 vs. 24 months, P = 0.001). The patients with EMP
had shorter OS than those without EMP in two age groups (32 vs. 42 and 15 vs. 24 months, P = 0.017 and 0.024,
respectively).
Conclusions: The results highlight that patients over 75 years and MM with EMP have a poorer outcome. While the CR
rate is higher in bortezomib-containing regimens, no significant improvement is noted in respect to the survival
outcomes; also, it cannot overcome the negative influence on survival of age and MM with EMP in elderly patients.
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Multiple myeloma (MM) is still an incurable disease,
representing the second most common hematologic
malignancy worldwide [1]. In Asian countries, there is
growing evidence that recognition of MM is increasing
rapidly, doubling of MM incidence in the last 10 years
[2–4]. In recent years, application of new drugs im-
proves the prognosis of MM patients, including the
elderly [5]. However, old patients often present with
comorbid conditions, which may decrease their ability to* Correspondence: huangzhongxia@sina.com
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inequality was also observed [6]. Currently, limited infor-
mation is available on the treatment of newly diagnosed
symptomatic multiple myeloma (NDMM) among elderly
Chinese patients. In this paper, initial treatment re-
sponse and survival of 61 cases of NDMM in elderly
Chinese patients are analyzed. This represents one of
the larger series examining the outcomes of elderly
patients with NDMM of a single center report from
China in recent years.Methods
The clinical data of 61 cases of NDMM elderly patients
had been diagnosed from Beijing Chao-Yang Hospitaldistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 2 Clinical characteristics of MM with EMP
Characteristics Overall
(n = 19)
A (≥65) B (≥75)
Age 72 (65–81) 69 (65–73) 77 (75–81)
Gender, n (%)
Male 10 (52.6 %) 7 (36.8 %) 3 (15.8 %)
Female 9 (47.4 %) 5 (26.3 %) 4 (21.1 %)
Heavy chain, n (%)
IgG 9 (47.4 %) 6 (31.6 %) 3 (15.8 %)
IgA 6 (31.6 %) 3 (15.8 %) 3 (15.8 %)
Light chain, n (%)
κ light chain 1 (5.3 %) 1 (5.3 %) 0
λ light chain 2 (10.6 %) 1 (5.3 %) 1 (5.3 %)
β2MG≥ 5.5 mg/l, n (%) 14 (73.7 %) 10 (52.6 %) 4 (21.1 %)
Sites of EMP, n (%)
1. Spinal canal 10 (52.6 %) 8 (42.1 %) 2 (10.5 %)
2. Pleura 5 (26.3 %) 0 5 (26.3 %)
3. Soft tissue 2 (10.5 %) 2 (10.5 %) 0
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They were divided into two groups as age: group A
(age ≥65, 65–74 years) and group B (age ≥75 years).
The diagnosis was based on the International Myeloma
Working Group (IMWG) diagnostic criteria. Patients
who had an organ involvement with light-chain amyl-
oidosis at the time of diagnosis were not included in
the current analysis. MM patients with extramedullary
plasmacytoma (EMP) was observed in 42.1 % patients
at diagnosis and 57.9 % patients during the disease
course, detected by magnetic resonance imaging (MRI),
computed tomography (CT), and/or histopathological
analysis of biopsy specimens.
In our study, patients received initial therapy with
regimens containing bortezomib or thalidomide, for
1–8 cycles. The mean duration of bortezomib-containing
regimens was 4 cycles. In patients achieving a complete
response (CR) or very good partial response (VGPR), the
regimen was repeated for 2–4 cycles as consolidation
therapy. In the absence of this, the treatment regimen
was modified. Maintenance therapy when utilized wasTable 1 General clinical characteristics of 61 cases of elderly
NDMM patients
Characteristics Overall Groups
Age (years) 72.5 (n = 61) A (≥65, n = 37) B (≥75, n = 24)
Gender
Male 38 (62.3 %) 23 (62.2 %) 14 (37.8)
Female 23 (37.7 %) 14 (37.8 %) 10 (41.7)
Calcium >11 mg/dl 4 (6.6 %) 2 (5.4 %) 2 (8.3 %)
Creatinine >2.0 mg/dl 12
(19.67 %)
7 (18.9 %) 5 (20.8 %)
Hemoglobin <10 g//L 48 (78.7 %) 28 (75.7 %) 20 (83.3 %)
Bone lesions 58 (95.1 %) 35 (94.6 %) 23 (95.8 %)
M component at diagnosis
Ig G 29 (47.5 %) 16 (43.2 %) 13 (54.2 %)
Ig A 16 (26.2 %) 11 (29.7 %) 5 (20.8 %)
Ig D 2 (3.3 %) 2 (5.4 %) 0
Light chain 13 (21.3 %) 8 (21.6 %) 5 (20.8 %)
Non-secretory 1 (1.6 %) 0 1 (4.2 %)
Stage of ISS
I 1 (1.6 %) 0 1 (4.2 %)
II 20 (32.8 %) 13 (35.1 %) 7 (29.2 %)
III 40 (65.6 %) 24 (64.9 %) 16 (66.7 %)




4 (6.6 %) 3 (11.5 %) 1 (3.8 %)
FISH 13 (21.3 %) 7 (26.9 %) 5 (19.2 %)
More than two
sites, n (%)
4 (21.1 %) 4 (21.1 %) 0
Plasma cell
percentage, n (%)





2 (33.3 %) 1 (16.7 %) 1 (16.7 %)
FISH 4 (66.7 %) 0 4 (66.7 %)mostly with thalidomide 100 mg/day; the other main-
tenance regimens included small doses of corticoste-
roids or lenalidomide. The patients who were unable to
tolerate the side effects or were in poor physical condi-
tion did not receive maintenance therapy.
Aspirin or low molecular weight heparin to prevent
venous thrombosis was routinely used in patients
without contraindications. Herpes zoster prophylaxis
was routinely used while patients were on bortezomib.
Bisphosphonates were used intravenously for myeloma
bone prophylaxis monthly.
In this elderly cohort, the patients who were diagnosed
as plasma cell leukemic and undergo autotransplant
were specifically excluded. Lenalidomide is approved on
sale in China in June 2013, but it has not been ap-
proved for treatment with the newly diagnosed mye-
loma patients. So in the current study, the patients
received lenalidomide only as maintenance.
The patients were assessed after the completion of
2 cycles of chemotherapy. Responses were graded using
the IMWG Uniform Response Criteria, and adverse
events were assessed according to the National Cancer
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Events (CTCAE) version 3.0.
Ethics statement
The study was approved by the Ethics Committee of
Beijing Chao-yang Hospital, Capital Medical University,
and follow-up information was obtained with consent of
the patients. All aspects of the study were conducted in
accordance with the principles of the Declaration of
Helsinki.
We used SPSS19.0 (SPSS Inc., Chicago, IL, USA) stat-
istical software for data analysis, and the Kaplan-Meier




1 13 q14 and 14q32 No FISH
2 46xx Amplification of 1q21
3 46xx IGH/FGFR3+
4 46xx Negative
5 46xx Amplification of 1q21










12 46xy 17p-, amplification of IGH
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15 46xy No FISH
16 46xy No FISH
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Twenty-five cases of patients with a chromosome examination, including four
cases of abnormal chromosomal changes. Nineteen patients had FISH testing;
among them, 13 patients had abnormal FISH changesprogression-free survival (PFS). P < 0.05 (log-rank test)
was considered statistically significant.Results
Of all the 61 cases of patients, the median age at diagno-
sis was 72.5 years. The male and the female were 62.3 %
(38/61) and 37.7 % (23/61) cases, respectively. In terms
of International Staging (ISS), 65.6 % (40/61) and 32.8 %
(20/61) and 1.6 % (1/61) cases were at stage III, II, and I,
respectively. Among them, 31.2 % (19/61) cases were di-
agnosed as MM with EMP, and the top three incidence
of position were spinal canal, pleural, and soft tissue.
The median follow-up was 38 months (24–96) at the last
follow-up. The general clinical characteristics were pro-
vided in Tables 1, 2, and 3.
Patients received bortezomib-containing regimens as
follows: bortezomib (Velcade, V or P) and dexamethasone
(D) or VD with cyclophosphamide (VCD) or with adriamy-
cin (A) (PAD). Patients received thalidomide-containing
regimens as follows: TAD or melphalan (M) and prednis-
one (P) thalidomide (T) (MPT) and CTD. Among the
above regimens, bortezomib (1.0–1.3 mg/m2) was given
intravenously or subcutaneously on days 1, 4, 8, and 11 of
a 21-day/cycle or weekly and dexamethasone 10–20 mg/
day on days 1, 4, 8, and 11/cycle or weekly, cyclophospha-
mide (200 mg/m2) and adriamycin (9 mg/m2). Melphalan
(4 mg/m2/day) and prednisone (40 mg/m2/day) were
administered orally on days 1–7, PO. Among CTD regi-
men, cyclophosphamide was given on days 1–4/15–18
intravenously and dexamethasone 10–20 mg/day on
days 1–4/15–18, PO, and thalidomide (100 mg) was
administered orally each day. In this study, treatment
regimens were heterogeneous, but VD or TAD was the
most commonly used.Table 4 Adverse events (AEs)




Case (%) (n = 39) (n = 22)
Gastrointestinal
symptoms
23 (60 %) 7 (31.8 %)
Infection (bacterial or/
and fungal)
12 (30.8 %) 14 (63.6 %)
Peripheral neuropathy 12 (30.8 %) 6 (27.3 %)
Cytopenia 8 (20.5 %) 4 (18.2 %)
Hyperglycemia 5 (12.8 %) 5 (22.7 %)
Thrombosis 0 3 (13.6 %)
Herpes zoster 2 (5.1 %) 0
Arrhythmia 1 (2.6 %) 1 (4.6 %)
Rash 1 (2.6 %) 1 (4.6 %)
Table 5 Comparison of efficacy of the two treatment options
groups
Treatment options Cases ORR% CR/n CR%
Bortezomib-containing regimens 39 94.9 61.51
Thalidomide-containing regimens 22 86.4 18.2
P value P > 0.05 P = 0.001
Comparison of bortezomib-containing regimens and thalidomide-containing
regimens treatment options. There were significant difference (P = 0.001) in
CR/nCR and no significant difference in ORR
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Adverse events (AEs) of two treatment groups were
shown in Table 4; the top three were gastrointestinal
symptoms, infection, and peripheral neuropathy. 1–2
grades and tolerated gastrointestinal reactions were
found in 30 cases; these included nausea, vomiting,
bloating, constipation, diarrhea, and anorexia, of 23
(60 %) cases occurred in the bortezomib-containing
regimen groups. All 26 cases suffered infection, most
of which were lung bacterial or/and fungal infection, of 14
(63.6 %) cases occurred in the thalidomide-containing reg-
imens groups, especially the patients application of TAD
regimen treatment. Eighteen cases suffered 1–2 grades of
peripheral neuropathy, and its incidence was similar in
both treatment groups of approximately 30 %. These in-
cluded numbness in hand and foot. The number of pa-
tients who suffered thrombocytopenia, elevated blood
glucose (among them three cases had steroid diabetes
because of glucocorticoid), and thrombosis were 12, 10,
and 3. The others included herpes zoster infection of
grades 3–4 (two cases), arrhythmia (two cases), and
rash (two cases).Fig. 1 Survival curves in two age groups. There was significant difference iTreatment response
Comparing two treatment groups, the ORR of bortezomib-
containing regimens was 94.9 % (37/39) and CR/nCR was
61.5 % (24/39). For the thalidomide-containing regimens,
its ORR was 86.4 % (19/22) and CR/nCR rate was 18.2 %
(4/22); there were significant difference (P = 0.001) in CR/
nCR and no significant difference in ORR (Table 5).
For two age groups, overall response rate (ORR) was
94.6 % (35/37) and CR/nCR rate was 48.7 % (18/37) in
group A. ORR was 87.5 % (21/24) and CR/nCR rate was
41.7 % in group B; there was no significant difference
between the two of them.
Of 42.2 % (8/19) cases of patients who suffered MM
with EMP at diagnosis, seven cases received bortezomib-
containing regimen treatment; their ORR was 85.5 %
and CR was 28.6 %.
Survival outcomes
Between the two age groups, OS was 37 and 19 months
and the median PFS was 22 and 14.5 months, respect-
ively, for group A and group B. There was a significant
difference in OS (P = 0.001) but no difference in PFS
(Fig. 1). OS rates at 1, 2, 3, 4, and 5 years were 82, 73,
60, 35, and 28 %, respectively, in group A. Meanwhile,
OS rates at 1, 2, 3, years were 54, 30, and 20 %, respect-
ively, in group B.
The patients with EMP had shorter OS than those
without EMP in two age groups; their OS was 32 vs. 42
in group A and 15 vs. 24 months in group B (P = 0.017
and 0.024), respectively (Fig. 2a, b).
Comparing the two treatment options of bortezomib-
containing and thalidomide-containing regimens in group
A, OS was 41 vs. 36.5 months and PFS was 23 vs. 16.5. Son OS between two age groups (P = 0.001) but no difference in PFS
Fig. 2 Survival curves in regard to EMP in two age groups. a OS of group A in regard to EMP. b OS of Group B in regard to EMP. The patients with EMP
had shorter OS than patients without EMP in two age groups A and B (P= 0.017 and 0.024), respectively
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vs. 11 months. There were no differences in these two
treatment options for OS and PFS.Discussion
Of the 205 consecutive MM patients whom we reviewed,
61 (29.76 %) cases were NDMM patients aged more
than 65 years and the others were younger than 65 years
old. Among them, 40 (65.6 %) cases were in end-stage
(ISS stage III) and 19 (31.2 %) cases of them had MM
with EMP. Our results are consistent with other reports
from Chinese patients; the median age of onset and inci-
dence of MM with EMP are different from the westerncountries although there have been no accurate esti-
mates of incidence of MM in China [2, 4, 7–10].
In the current study, comparing the bortezomib-
containing regimens and thalidomide-containing regi-
mens, the rate and degree of remission all favored the
efficacy of bortezomib [5, 10–17], regardless of the age.
Nevertheless, further analysis found that age and MM
with EMP had a negative impact on survival. Therefore,
the high remission rate benefited by bortezomib did not
transfer into a survival advantage. It can be seen among
patients ≥75 years, whose PFS and OS were worse com-
pared to those over 65 years, such results clearly indicated
greater influence on the survival of the elderly patients,
especially the patients of age over 75 years [6, 15]. For
An et al. World Journal of Surgical Oncology  (2015) 13:239 Page 6 of 6patients with EMP, either two different age groups, whose
OS was worse with EMP or infiltration of extramedullary
patients, further confirmed MM with EMP adversely
affect the prognosis [7, 18].
There was no significant survival benefit in older
NDMM patients on protease inhibitor therapy in this
study, which was inconsistent with other investigators
[16–19]. Moreover, the remission rate with bortezomib
was not consistent with the OS in our study. One pos-
sible explanation for such differences is the fact that the
patients of the current study came from a myeloma
medical research center and most of the patients were
end-stage or with many other poor prognostic factors,
such as with higher incidence of EMP. An alternative ex-
planation is that elderly patients have poor tolerance to
chemotherapy; in addition, poor compliance also con-
tributes interruption of treatment or inability to adhere
to maintenance therapy.
Conclusions
In general, the current results provide evidence that
bortezomib-containing regimens has a deeper response
than thalidomide regimens in elderly MM patients, espe-
cially in patients of age older than 75 years; however, it
cannot overcome the negative influence on survival of
age and MM with EMP.
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